Company profile
Ticker
IQMD
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
862283527
IQMD stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
12 May 23
25-NSE
Exchange delisting
2 May 23
8-K
Intelligent Medicine Acquisition Corp. Announces it Will Redeem its Public Shares
26 Apr 23
10-K
2022 FY
Annual report
17 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Apr 23
NT 10-K
Notice of late annual filing
3 Apr 23
425
Business combination disclosure
22 Feb 23
8-K
Entry into a Material Definitive Agreement
22 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
9 Feb 23
Latest ownership filings
3
Initial statement of insider ownership
27 Apr 23
SC 13G/A
Saba Capital Management, L.P.
13 Apr 23
4
Boaz Weinstein
28 Feb 23
SC 13D
Intelligent Medicine Sponsor LLC
21 Feb 23
4
Change in insider ownership
10 Feb 23
3/A
Boaz Weinstein
7 Jun 22
SC 13G/A
Saba Capital Management, L.P.
9 May 22
3
Boaz Weinstein
9 May 22
SC 13G/A
Saba Capital Management, L.P.
14 Feb 22
SC 13G/A
Sculptor Capital LP
11 Feb 22
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 50.15 k | 50.15 k | 50.15 k | 50.15 k | 50.15 k | |
Cash burn (monthly) | 36.85 k | 44.93 k | (no burn) | (no burn) | 15.52 k | |
Cash used (since last report) | 415.74 k | 506.89 k | n/a | n/a | 175.08 k | |
Cash remaining | -365.59 k | -456.74 k | n/a | n/a | -124.93 k | |
Runway (months of cash) | -9.9 | -10.2 | n/a | n/a | -8.1 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 1 |
Closed positions | 47 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 51.70 mm |
Total shares | 4.75 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intelligent Medicine Sponsor | 4.70 mm | $47.38 mm |
Davidson Kempner Partners | 50.00 k | $2.30 mm |
Robinson Capital Management | 196.00 | $2.03 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Feb 23 | Saba Capital Management | Common Stock | Sale back to company | Dispose D | Yes | No | 10.34 | 2,170,581 | 22.44 mm | 0 |
8 Feb 23 | Intelligent Medicine Sponsor | Class B Common Stock Class A Common Stock | Gift | Dispose G | No | No | 0 | 200,000 | 0.00 | 4,700,000 |